Protection of mice and swine against infection with Actinobacillus pleuropneumoniae by vaccination

Beaudet, Réjean; McSween, G.; Boulay, Gaston; Rousseau, Paul; Bisaillon, Jean‐Guy; Descôteaux, J P; Ruppanner, R

doi:10.1016/0378-1135(94)90087-6

Cited by 19 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antibodies against capsule, lipopolysaccharides and outer membrane proteins serve as opsonins, thereby enabling phagocytosis by neutrophils (Thwaits and Kadis, 1991; Byrd and Kadis, 1992), but do not destroy A. pleuropneumoniae cells by complement binding (Rycroft and Cullen, 1990). Although these antibodies provide only partial protection against challenge by homologous A. pleuropneumoniae serotypes and, particularly, by heterologous serotypes (Inzana et al, 1988, 1991, 1993; Jansen, 1994; Beaudet et al, 1994), respective antigens contribute to typical lesion formation (Fenwick and Osburn, 1986; Paradis et al, 1994; Fenwick, 1994). Non‐capsulated A. pleuropneumoniae mutants are not virulent, but are useful as vaccines in protecting against swine pleuropneumonia (Inzana, 1996).…”

Section: Introductionmentioning

confidence: 99%

Overcoming Immune Tolerance During Oral Vaccination AgainstActinobacillus pleuropneumoniae

Silin

Lyubomska

2002

Journal of Veterinary Medicine, Series B

View full text Add to dashboard Cite

In the preliminary study mice were vaccinated orally with Actinobacillus pleuropneumoniae microsphere oral vaccine. The lung and eye mucous membranes of these mice did not contain increased immunoglobulin A (IgA) following the initial oral vaccination, possibly through antibody persistence and the phenomenon of immune exclusion. A similar tendency was found for serum IgG. However, after the second vaccination, IgA still did not increase significantly, which could be attributed to immune suppression due to the possibility of the intestine inducing immune tolerance. Only the third vaccination overcame this effect and increased the level of IgA. In order to achieve a high systemic and local immune response this study attempted to overcome the initial tolerance to oral vaccination by using temporary immunosuppression, increasing antigen dose, and prolonging vaccine influence. Triamcinolone, used in the later productive phase of the immune response after the first and second vaccinations, but restricted in the inductive phase of the second and third vaccinations, could disable immune tolerance. Suppression of antibody production before the next induction of the immune response by an oral vaccine combined with suppression of cell-suppressor activity led to the creation of systemic immunity with the possibility of high levels of A. pleuropneumoniae growth inhibition. Increased antigen doses or durable consumption of antigen could overcome immune exclusion of antigen by primary antibodies. Even very low doses of vaccine (4.5 mg) could induce a primary immune response, and a dose increased by 10-fold for the second vaccination could overcome tolerance and maintain high systemic immunity. Chronic consumption of oral vaccine led to benefits in the quantity of local (not systemic) antibodies. The outcomes of the study can be adapted for practical oral immunization of pigs.

show abstract

Section: Introductionmentioning

confidence: 99%

Overcoming Immune Tolerance During Oral Vaccination AgainstActinobacillus pleuropneumoniae

Silin

Lyubomska

2002

Journal of Veterinary Medicine, Series B

View full text Add to dashboard Cite

show abstract

“…Although swine is a natural host for A. pleuropneumoniae infection and natural infection and symptoms are developed on respiratory tract, several reports previously proved that mouse challenge model through intraperitoneal injection of A. pleuropneumoniae is successfully applicable as a protective experimental model before an actual test with swine (Beaudet et al, 1994;Prideaux et al, 1998;Seah et al, 2002;Lee et al, 2006;Ramjeet et al, 2008).…”

Section: Differential Protective Immunity Induced By Individual Apxiimentioning

confidence: 99%

“…Mice were challenged intraperitoneally with either 400 μl of A. pleuropneumoniae preparation (∼1 x 10 8 CFU) or with control buffer seven days after the last boost immunization. The numbers of mice surviving three days after the challenge were recorded and considered to be successfully vaccinated against A. pleuropneumoniae challenge as previously reported (Beaudet et al, 1994;Prideaux et al, 1998;Seah et al, 2002;Lee et al, 2006;Ramjeet et al, 2008).…”

Section: Challenge Experiments With a Pleuropneumoniaementioning

confidence: 99%

Characterization of Antigenic Determinants in ApxIIA Exotoxin Capable of Inducing Protective Immunity toActinobacillus pleuropneumoniaeChallenge

Seo

Kim

et al. 2011

Immunological Investigations

View full text Add to dashboard Cite

Actinobacillus pleuropneumoniae is the causative agent of porcine pleuropneumonia. Among the virulence factors of the pathogen, ApxIIA, a bacterial exotoxin, is expressed by many serotypes and presents a plausible target for vaccine development. We characterized the region within ApxIIA that induces a protective immune response against bacterial infection using mouse challenge model. Recombinant proteins spanning the length of ApxIIA were produced and antiserum to the full-length ApxIIA was induced in mice. This antiserum recognized fragments #2, #3 and #5 with high binding specificity, but showed poor recognition for fragments #1 and #4. Of the antisera induced in mice by injection of each fragments, only the antiserum to fragment #4 failed to efficiently recognize the full-length antigen, although the individual antisera recognized their cognate antigens with almost equal efficiency. The protective potency of the immunogenic proteins against a challenge injection of bacteria in vivo correlated well with the antibody titer. Fragment #5 induced the highest level of protective activity, comparable to that by the full-length protein. These results support the use of fragment #5 to produce a vaccine against A. pleuropneumoniae challenge, since the small antigen peptide is easier to handle than is the full-length protein and can be expressed efficiently in heterologous expression systems.

show abstract

“…The murine model for APP respiratory tract infection has been experimentally developed to evaluate the efficacy of vaccines [1]. According to previous studies, this model is a far less laborious and resource intensive than the standard porcine model [2,3]. 15 serovars have been reported over the past several decades, and a new serovar 16 was reported in 2017 [4,5].…”

Section: Introductionmentioning

confidence: 99%

Galactose-1-phosphate uridyltransferase (GalT), an in vivo-induced antigen of Actinobacillus pleuropneumoniae serovar 5b strain L20, provided immunoprotection against serovar 1 strain MS71

et al. 2018

View full text Add to dashboard Cite

GALT is an important antigen of Actinobacillus pleuropneumoniae (APP), which was shown to provide partial protection against APP infection in a previous study in our lab. The main purpose of the present study is to investigate GALT induced cross-protection between different APP serotypes and elucidate key mechanisms of the immune response to GALT antigenic stimulation. Bioinformatic analysis demonstrated that galT is a highly conserved gene in APP, widely distributed across multiple pathogenic strains. Homologies between any two strains ranges from 78.9% to 100% regarding the galT locus. Indirect enzyme-linked immunosorbent assay (ELISA) confirmed that GALT specific antibodies could not be induced by inactivated APP L20 or MS71 whole cell bacterin preparations. A recombinant fusion GALT protein derived from APP L20, however has proven to be an effective cross-protective antigen against APP sevorar 1 MS71 (50%, 4/8) and APP sevorar 5b L20 (75%, 6/8). Histopathological examinations have confirmed that recombinant GALT vaccinated animals showed less severe pathological signs in lung tissues than negative controls after APP challenge. Immunohistochemical (IHC) analysis indicated that the infiltration of neutrophils in the negative group is significantly increased compared with that in the normal control (P<0.001) and that in surviving animals is decreased compared to the negative group. Anti-GALT antibodies were shown to mediate phagocytosis of neutrophils. After interaction with anti-GALT antibodies, survival rate of APP challenged vaccinated animals was significantly reduced (P<0.001). This study demonstrated that GALT is an effective cross-protective antigen, which could be used as a potential vaccine candidate against multiple APP serotypes.

show abstract

Protection of mice and swine against infection with Actinobacillus pleuropneumoniae by vaccination

Cited by 19 publications

References 22 publications

Overcoming Immune Tolerance During Oral Vaccination AgainstActinobacillus pleuropneumoniae

Overcoming Immune Tolerance During Oral Vaccination AgainstActinobacillus pleuropneumoniae

Characterization of Antigenic Determinants in ApxIIA Exotoxin Capable of Inducing Protective Immunity toActinobacillus pleuropneumoniaeChallenge

Galactose-1-phosphate uridyltransferase (GalT), an in vivo-induced antigen of Actinobacillus pleuropneumoniae serovar 5b strain L20, provided immunoprotection against serovar 1 strain MS71

Contact Info

Product

Resources

About